What is the projected market valuation for the Inhaled Nitric Oxide No Delivery System Market in 2035?

The projected market valuation for the Inhaled Nitric Oxide No Delivery System Market in 2035 is 2.619 USD Billion. Read More

What was the market valuation for the Inhaled Nitric Oxide No Delivery System Market in 2024?

The market valuation for the Inhaled Nitric Oxide No Delivery System Market in 2024 was 1.268 USD Billion. Read More

What is the expected CAGR for the Inhaled Nitric Oxide No Delivery System Market from 2025 to 2035?

The expected CAGR for the Inhaled Nitric Oxide No Delivery System Market during the forecast period 2025 - 2035 is 6.82%. Read More

Which companies are considered key players in the Inhaled Nitric Oxide No Delivery System Market?

Key players in the market include Mallinckrodt Pharmaceuticals, Bellerophon Therapeutics, United Therapeutics Corporation, and others. Read More

What are the projected revenues for the 100 ppm concentration segment in 2025?

The projected revenues for the 100 ppm concentration segment in 2025 are expected to range from 0.254 to 0.516 USD Billion. Read More

How does the revenue for the Nasal Cannula delivery system compare to other delivery systems?

The revenue for the Nasal Cannula delivery system is projected to be between 0.38 and 0.78 USD Billion, making it one of the leading delivery systems. Read More

What is the anticipated revenue for the Pulmonary Hypertension indication segment in 2025?

The anticipated revenue for the Pulmonary Hypertension indication segment in 2025 is expected to range from 0.5 to 0.9 USD Billion. Read More

Which patient population segment is projected to generate the highest revenue in 2025?

The Newborns patient population segment is projected to generate the highest revenue, estimated between 0.4 and 0.8 USD Billion. Read More

What is the expected revenue range for hospitals as end users of the Inhaled Nitric Oxide No Delivery System?

The expected revenue range for hospitals as end users is projected to be between 0.76 and 1.55 USD Billion. Read More

How does the revenue for the Chronic Obstructive Pulmonary Disease indication segment compare to Asthma?

The revenue for the Chronic Obstructive Pulmonary Disease indication segment is projected to be between 0.268 and 0.719 USD Billion, which is higher than the Asthma segment, estimated at 0.2 to 0.4 USD Billion. Read More

Inhaled Nitric Oxide No Delivery System Market

ID: MRFR/CnM/23355-HCR

111 Pages

Chitranshi Jaiswal

Last Updated: April 23, 2026

Inhaled Nitric Oxide No Delivery System Market Research Report: By Inhaled Nitric Oxide Concentration (100 ppm, 200 ppm, 300 ppm, 400 ppm, 500 ppm), By Delivery System (Nasal Cannula, Tracheal Tube, Ventilator, Face Mask), By Patient Population (Newborns, Children, Adults, Older Adults), By Indication (Pulmonary Hypertension, Respiratory Distress Syndrome, Asthma, Chronic Obstructive Pulmonary Disease), By End User (Hospitals, Clinics, Ambulatory Surgery Centers) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

Inhaled Nitric Oxide No Delivery System Market Infographic

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Chemicals and Materials, BY Inhaled Nitric Oxide Concentration (USD Billion) | |
  1. 4.1.1 100 ppm | |
  2. 4.1.2 200 ppm | |
  3. 4.1.3 300 ppm | |
  4. 4.1.4 400 ppm | |
  5. 4.1.5 500 ppm |
2. 4.2 Chemicals and Materials, BY Delivery System (USD Billion) | |
  1. 4.2.1 Nasal Cannula | |
  2. 4.2.2 Tracheal Tube | |
  3. 4.2.3 Ventilator | |
  4. 4.2.4 Face Mask |
3. 4.3 Chemicals and Materials, BY Patient Population (USD Billion) | |
  1. 4.3.1 Newborns | |
  2. 4.3.2 Children | |
  3. 4.3.3 Adults | |
  4. 4.3.4 Older Adults |
4. 4.4 Chemicals and Materials, BY Indication (USD Billion) | |
  1. 4.4.1 Pulmonary Hypertension | |
  2. 4.4.2 Respiratory Distress Syndrome | |
  3. 4.4.3 Asthma | |
  4. 4.4.4 Chronic Obstructive Pulmonary Disease |
5. 4.5 Chemicals and Materials, BY End User (USD Billion) | |
  1. 4.5.1 Hospitals | |
  2. 4.5.2 Clinics | |
  3. 4.5.3 Ambulatory Surgery Centers |
6. 4.6 Chemicals and Materials, BY Region (USD Billion) | |
  1. 4.6.1 North America | | |
    1. 4.6.1.1 US | | |
    2. 4.6.1.2 Canada | |
  2. 4.6.2 Europe | | |
    1. 4.6.2.1 Germany | | |
    2. 4.6.2.2 UK | | |
    3. 4.6.2.3 France | | |
    4. 4.6.2.4 Russia | | |
    5. 4.6.2.5 Italy | | |
    6. 4.6.2.6 Spain | | |
    7. 4.6.2.7 Rest of Europe | |
  3. 4.6.3 APAC | | |
    1. 4.6.3.1 China | | |
    2. 4.6.3.2 India | | |
    3. 4.6.3.3 Japan | | |
    4. 4.6.3.4 South Korea | | |
    5. 4.6.3.5 Malaysia | | |
    6. 4.6.3.6 Thailand | | |
    7. 4.6.3.7 Indonesia | | |
    8. 4.6.3.8 Rest of APAC | |
  4. 4.6.4 South America | | |
    1. 4.6.4.1 Brazil | | |
    2. 4.6.4.2 Mexico | | |
    3. 4.6.4.3 Argentina | | |
    4. 4.6.4.4 Rest of South America | |
  5. 4.6.5 MEA | | |
    1. 4.6.5.1 GCC Countries | | |
    2. 4.6.5.2 South Africa | | |
    3. 4.6.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Mallinckrodt Pharmaceuticals (IE) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Bellerophon Therapeutics (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 United Therapeutics Corporation (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 OxySure Therapeutics (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 AstraZeneca (GB) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Pfizer Inc. (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Novartis AG (CH) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Eli Lilly and Company (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
7. 6.4 US MARKET ANALYSIS BY DELIVERY SYSTEM |
8. 6.5 US MARKET ANALYSIS BY PATIENT POPULATION |
9. 6.6 US MARKET ANALYSIS BY INDICATION |
10. 6.7 US MARKET ANALYSIS BY END USER |
11. 6.8 CANADA MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
12. 6.9 CANADA MARKET ANALYSIS BY DELIVERY SYSTEM |
13. 6.10 CANADA MARKET ANALYSIS BY PATIENT POPULATION |
14. 6.11 CANADA MARKET ANALYSIS BY INDICATION |
15. 6.12 CANADA MARKET ANALYSIS BY END USER |
16. 6.13 EUROPE MARKET ANALYSIS |
17. 6.14 GERMANY MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
18. 6.15 GERMANY MARKET ANALYSIS BY DELIVERY SYSTEM |
19. 6.16 GERMANY MARKET ANALYSIS BY PATIENT POPULATION |
20. 6.17 GERMANY MARKET ANALYSIS BY INDICATION |
21. 6.18 GERMANY MARKET ANALYSIS BY END USER |
22. 6.19 UK MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
23. 6.20 UK MARKET ANALYSIS BY DELIVERY SYSTEM |
24. 6.21 UK MARKET ANALYSIS BY PATIENT POPULATION |
25. 6.22 UK MARKET ANALYSIS BY INDICATION |
26. 6.23 UK MARKET ANALYSIS BY END USER |
27. 6.24 FRANCE MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
28. 6.25 FRANCE MARKET ANALYSIS BY DELIVERY SYSTEM |
29. 6.26 FRANCE MARKET ANALYSIS BY PATIENT POPULATION |
30. 6.27 FRANCE MARKET ANALYSIS BY INDICATION |
31. 6.28 FRANCE MARKET ANALYSIS BY END USER |
32. 6.29 RUSSIA MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
33. 6.30 RUSSIA MARKET ANALYSIS BY DELIVERY SYSTEM |
34. 6.31 RUSSIA MARKET ANALYSIS BY PATIENT POPULATION |
35. 6.32 RUSSIA MARKET ANALYSIS BY INDICATION |
36. 6.33 RUSSIA MARKET ANALYSIS BY END USER |
37. 6.34 ITALY MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
38. 6.35 ITALY MARKET ANALYSIS BY DELIVERY SYSTEM |
39. 6.36 ITALY MARKET ANALYSIS BY PATIENT POPULATION |
40. 6.37 ITALY MARKET ANALYSIS BY INDICATION |
41. 6.38 ITALY MARKET ANALYSIS BY END USER |
42. 6.39 SPAIN MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
43. 6.40 SPAIN MARKET ANALYSIS BY DELIVERY SYSTEM |
44. 6.41 SPAIN MARKET ANALYSIS BY PATIENT POPULATION |
45. 6.42 SPAIN MARKET ANALYSIS BY INDICATION |
46. 6.43 SPAIN MARKET ANALYSIS BY END USER |
47. 6.44 REST OF EUROPE MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
48. 6.45 REST OF EUROPE MARKET ANALYSIS BY DELIVERY SYSTEM |
49. 6.46 REST OF EUROPE MARKET ANALYSIS BY PATIENT POPULATION |
50. 6.47 REST OF EUROPE MARKET ANALYSIS BY INDICATION |
51. 6.48 REST OF EUROPE MARKET ANALYSIS BY END USER |
52. 6.49 APAC MARKET ANALYSIS |
53. 6.50 CHINA MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
54. 6.51 CHINA MARKET ANALYSIS BY DELIVERY SYSTEM |
55. 6.52 CHINA MARKET ANALYSIS BY PATIENT POPULATION |
56. 6.53 CHINA MARKET ANALYSIS BY INDICATION |
57. 6.54 CHINA MARKET ANALYSIS BY END USER |
58. 6.55 INDIA MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
59. 6.56 INDIA MARKET ANALYSIS BY DELIVERY SYSTEM |
60. 6.57 INDIA MARKET ANALYSIS BY PATIENT POPULATION |
61. 6.58 INDIA MARKET ANALYSIS BY INDICATION |
62. 6.59 INDIA MARKET ANALYSIS BY END USER |
63. 6.60 JAPAN MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
64. 6.61 JAPAN MARKET ANALYSIS BY DELIVERY SYSTEM |
65. 6.62 JAPAN MARKET ANALYSIS BY PATIENT POPULATION |
66. 6.63 JAPAN MARKET ANALYSIS BY INDICATION |
67. 6.64 JAPAN MARKET ANALYSIS BY END USER |
68. 6.65 SOUTH KOREA MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
69. 6.66 SOUTH KOREA MARKET ANALYSIS BY DELIVERY SYSTEM |
70. 6.67 SOUTH KOREA MARKET ANALYSIS BY PATIENT POPULATION |
71. 6.68 SOUTH KOREA MARKET ANALYSIS BY INDICATION |
72. 6.69 SOUTH KOREA MARKET ANALYSIS BY END USER |
73. 6.70 MALAYSIA MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
74. 6.71 MALAYSIA MARKET ANALYSIS BY DELIVERY SYSTEM |
75. 6.72 MALAYSIA MARKET ANALYSIS BY PATIENT POPULATION |
76. 6.73 MALAYSIA MARKET ANALYSIS BY INDICATION |
77. 6.74 MALAYSIA MARKET ANALYSIS BY END USER |
78. 6.75 THAILAND MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
79. 6.76 THAILAND MARKET ANALYSIS BY DELIVERY SYSTEM |
80. 6.77 THAILAND MARKET ANALYSIS BY PATIENT POPULATION |
81. 6.78 THAILAND MARKET ANALYSIS BY INDICATION |
82. 6.79 THAILAND MARKET ANALYSIS BY END USER |
83. 6.80 INDONESIA MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
84. 6.81 INDONESIA MARKET ANALYSIS BY DELIVERY SYSTEM |
85. 6.82 INDONESIA MARKET ANALYSIS BY PATIENT POPULATION |
86. 6.83 INDONESIA MARKET ANALYSIS BY INDICATION |
87. 6.84 INDONESIA MARKET ANALYSIS BY END USER |
88. 6.85 REST OF APAC MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
89. 6.86 REST OF APAC MARKET ANALYSIS BY DELIVERY SYSTEM |
90. 6.87 REST OF APAC MARKET ANALYSIS BY PATIENT POPULATION |
91. 6.88 REST OF APAC MARKET ANALYSIS BY INDICATION |
92. 6.89 REST OF APAC MARKET ANALYSIS BY END USER |
93. 6.90 SOUTH AMERICA MARKET ANALYSIS |
94. 6.91 BRAZIL MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
95. 6.92 BRAZIL MARKET ANALYSIS BY DELIVERY SYSTEM |
96. 6.93 BRAZIL MARKET ANALYSIS BY PATIENT POPULATION |
97. 6.94 BRAZIL MARKET ANALYSIS BY INDICATION |
98. 6.95 BRAZIL MARKET ANALYSIS BY END USER |
99. 6.96 MEXICO MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
100. 6.97 MEXICO MARKET ANALYSIS BY DELIVERY SYSTEM |
101. 6.98 MEXICO MARKET ANALYSIS BY PATIENT POPULATION |
102. 6.99 MEXICO MARKET ANALYSIS BY INDICATION |
103. 6.100 MEXICO MARKET ANALYSIS BY END USER |
104. 6.101 ARGENTINA MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
105. 6.102 ARGENTINA MARKET ANALYSIS BY DELIVERY SYSTEM |
106. 6.103 ARGENTINA MARKET ANALYSIS BY PATIENT POPULATION |
107. 6.104 ARGENTINA MARKET ANALYSIS BY INDICATION |
108. 6.105 ARGENTINA MARKET ANALYSIS BY END USER |
109. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
110. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY DELIVERY SYSTEM |
111. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT POPULATION |
112. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION |
113. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
114. 6.111 MEA MARKET ANALYSIS |
115. 6.112 GCC COUNTRIES MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
116. 6.113 GCC COUNTRIES MARKET ANALYSIS BY DELIVERY SYSTEM |
117. 6.114 GCC COUNTRIES MARKET ANALYSIS BY PATIENT POPULATION |
118. 6.115 GCC COUNTRIES MARKET ANALYSIS BY INDICATION |
119. 6.116 GCC COUNTRIES MARKET ANALYSIS BY END USER |
120. 6.117 SOUTH AFRICA MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
121. 6.118 SOUTH AFRICA MARKET ANALYSIS BY DELIVERY SYSTEM |
122. 6.119 SOUTH AFRICA MARKET ANALYSIS BY PATIENT POPULATION |
123. 6.120 SOUTH AFRICA MARKET ANALYSIS BY INDICATION |
124. 6.121 SOUTH AFRICA MARKET ANALYSIS BY END USER |
125. 6.122 REST OF MEA MARKET ANALYSIS BY INHALED NITRIC OXIDE CONCENTRATION |
126. 6.123 REST OF MEA MARKET ANALYSIS BY DELIVERY SYSTEM |
127. 6.124 REST OF MEA MARKET ANALYSIS BY PATIENT POPULATION |
128. 6.125 REST OF MEA MARKET ANALYSIS BY INDICATION |
129. 6.126 REST OF MEA MARKET ANALYSIS BY END USER |
130. 6.127 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS |
131. 6.128 RESEARCH PROCESS OF MRFR |
132. 6.129 DRO ANALYSIS OF CHEMICALS AND MATERIALS |
133. 6.130 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS |
134. 6.131 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS |
135. 6.132 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS |
136. 6.133 CHEMICALS AND MATERIALS, BY INHALED NITRIC OXIDE CONCENTRATION, 2024 (% SHARE) |
137. 6.134 CHEMICALS AND MATERIALS, BY INHALED NITRIC OXIDE CONCENTRATION, 2024 TO 2035 (USD Billion) |
138. 6.135 CHEMICALS AND MATERIALS, BY DELIVERY SYSTEM, 2024 (% SHARE) |
139. 6.136 CHEMICALS AND MATERIALS, BY DELIVERY SYSTEM, 2024 TO 2035 (USD Billion) |
140. 6.137 CHEMICALS AND MATERIALS, BY PATIENT POPULATION, 2024 (% SHARE) |
141. 6.138 CHEMICALS AND MATERIALS, BY PATIENT POPULATION, 2024 TO 2035 (USD Billion) |
142. 6.139 CHEMICALS AND MATERIALS, BY INDICATION, 2024 (% SHARE) |
143. 6.140 CHEMICALS AND MATERIALS, BY INDICATION, 2024 TO 2035 (USD Billion) |
144. 6.141 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE) |
145. 6.142 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Billion) |
146. 6.143 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
147. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
148. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.2.5 BY END USER, 2025-2035 (USD Billion) |
149. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.3.5 BY END USER, 2025-2035 (USD Billion) |
150. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.4.5 BY END USER, 2025-2035 (USD Billion) |
151. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.5.5 BY END USER, 2025-2035 (USD Billion) |
152. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.6.5 BY END USER, 2025-2035 (USD Billion) |
153. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.7.5 BY END USER, 2025-2035 (USD Billion) |
154. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.8.5 BY END USER, 2025-2035 (USD Billion) |
155. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.9.5 BY END USER, 2025-2035 (USD Billion) |
156. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.10.5 BY END USER, 2025-2035 (USD Billion) |
157. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.11.5 BY END USER, 2025-2035 (USD Billion) |
158. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.12.5 BY END USER, 2025-2035 (USD Billion) |
159. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.13.5 BY END USER, 2025-2035 (USD Billion) |
160. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.14.5 BY END USER, 2025-2035 (USD Billion) |
161. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.15.5 BY END USER, 2025-2035 (USD Billion) |
162. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.16.5 BY END USER, 2025-2035 (USD Billion) |
163. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.17.5 BY END USER, 2025-2035 (USD Billion) |
164. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.18.5 BY END USER, 2025-2035 (USD Billion) |
165. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.19.5 BY END USER, 2025-2035 (USD Billion) |
166. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.20.5 BY END USER, 2025-2035 (USD Billion) |
167. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.21.5 BY END USER, 2025-2035 (USD Billion) |
168. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.22.5 BY END USER, 2025-2035 (USD Billion) |
169. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.23.5 BY END USER, 2025-2035 (USD Billion) |
170. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.24.5 BY END USER, 2025-2035 (USD Billion) |
171. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.25.5 BY END USER, 2025-2035 (USD Billion) |
172. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.26.5 BY END USER, 2025-2035 (USD Billion) |
173. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.27.5 BY END USER, 2025-2035 (USD Billion) |
174. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.28.5 BY END USER, 2025-2035 (USD Billion) |
175. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.29.5 BY END USER, 2025-2035 (USD Billion) |
176. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY INHALED NITRIC OXIDE CONCENTRATION, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY DELIVERY SYSTEM, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY PATIENT POPULATION, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY INDICATION, 2025-2035 (USD Billion) | |
  5. 7.30.5 BY END USER, 2025-2035 (USD Billion) |
177. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
178. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Chemicals and Materials Market Segmentation

Chemicals and Materials By Inhaled Nitric Oxide Concentration (USD Billion, 2025-2035)

100 ppm
200 ppm
300 ppm
400 ppm
500 ppm

Chemicals and Materials By Delivery System (USD Billion, 2025-2035)

Nasal Cannula
Tracheal Tube
Ventilator
Face Mask

Chemicals and Materials By Patient Population (USD Billion, 2025-2035)

Newborns
Children
Adults
Older Adults

Chemicals and Materials By Indication (USD Billion, 2025-2035)

Pulmonary Hypertension
Respiratory Distress Syndrome
Asthma
Chronic Obstructive Pulmonary Disease

Chemicals and Materials By End User (USD Billion, 2025-2035)

Hospitals
Clinics
Ambulatory Surgery Centers

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓